Our organization is trying a therapeutic interchange to Levemir. We have some exception criteria to allow patients to stay on Lantus, which we are guessing will be about 30% of patients.
Currently we stock Lantus as a MDV in our ADC and send up Levemir as a patient specific medication. With the change, we are considering stocking both Levemir and Lantus as MDV in the ADC.
Do any other organizations allow this and what safety measures have you been able to implement to prevent confusion with the two brands.
Thank you,
Carey Estes, MSN, RN, CPPS
Quality Manager - Medication Safety
Mission Hospital
Asheville, NC 28803